|
|
Vaccine Detail
|
HyperAcute - Breast cancer vaccine |
| Vaccine Information |
- Vaccine Name: HyperAcute - Breast cancer vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: alpha (1,3) galactosyl-epitopes (alpha-gal) (NCT00090480)
- Immunization Route: Intradermal injection (i.d.)
- Description: The expression of the murine alpha (1,3) galactosyltransferase [alpha (1,3) GT] gene results in the cell surface expression of alpha (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids. This vaccine is composed of irradiated allogeneic breast cancer cell lines (HAB-1 and HAB-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink. (NCT00090480)
|
| Host Response |
|
|
| References |
NCT00090480: Vaccine Treatment for Advanced Breast Cancer [https://clinicaltrials.gov/study/NCT00090480]
|
|
